Skip to main content

Advertisement

SpringerLink
Log in

Progressive Supranuclear Palsy

Clinical Features, Pathophysiology and Management

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Progressive supranuclear palsy (PSP) is a degenerative condition of unknown aetiology that produces an akinetic-rigid form of parkinsonism characterised by early falls and abnormalities of extraocular movements. Mean age of onset is approximately 63 years, and mean survival from symptom onset is 9 years. Men are much more frequently affected than women. The classic clinical finding is supranuclear ophthalmoplegia, which may not present until late in the illness, if at all.

The clinical diagnosis of PSP can be difficult to make, as the sites of pathology are heterogeneous. Structural and functional neuroimaging studies, although not specific for PSP, may be of some assistance in making the diagnosis. The definitive diagnosis of PSP requires the presence of both clinical and neuropathological evidence. Multiple anatomical sites are affected in PSP. The most consistently involved are the subthalamic nucleus, globus pallidus interna and externa, pontine nuclei, periaqueductal grey matter and the substantia nigra. The location of the pathology accounts for the clinical features.

The histological hallmark of PSP is the presence of globose neurofibrillary tangles in the affected subcortical nuclei. Neurofibrillary tangles are composed of abnormally phosphorylated tau, a microtubule-associated protein that is involved in maintenance of the cytoskeleton. Abnormalities near or in the gene coding for tau are implicated in the pathogenesis of PSP.

The multiple neurotransmitter abnormalities, including those affecting dopamine, acetylcholine, γ-aminobutyric acid and norepinephrine (noradrenaline) systems and pathways, as well as both pre- and post-synaptic pathology, make pharmacological therapy of PSP a challenge. Although an individual patient may respond to a drug, in general patients with PSP have a minimal response and a short duration of sustained benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I

Similar content being viewed by others

References

  1. Goetz CG. An early photographic case of probable supranuclear palsy. Mov Disord 1996; 11(6): 617–8

    Article  PubMed  CAS  Google Scholar 

  2. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10: 333–59

    Article  PubMed  CAS  Google Scholar 

  3. Hughes AJ, Ben-Shlomo Y, Daniel SE, et al. What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology 1992; 42: 1142–6

    Article  PubMed  CAS  Google Scholar 

  4. Bower JH, Maraganore DM, McDonnell SK, et al. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997; 49: 1284–8

    Article  PubMed  CAS  Google Scholar 

  5. Nath U, Burn DJ. The epidemiology of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Parkinsonism Related Disord 2000; 6: 145–53

    Article  Google Scholar 

  6. Schräg A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a crosssection study. Lancet 1999; 354: 1771–5

    Article  PubMed  Google Scholar 

  7. McCrank E, Rabheru K. Four cases of progressive supranuclear palsy in patients exposed to organic solvents. Can J Psychiatry 1989; 34: 934–5

    PubMed  CAS  Google Scholar 

  8. Davis PH, Golbe LI, Duvoisin RC, et al. Risk factors for progressive supranuclear palsy. Neurology 1988; 38: 1546–52

    Article  PubMed  CAS  Google Scholar 

  9. Golbe LI, Rubin RS, Cody RP, et al. Follow-up study of risk factors in progressive supranuclear palsy. Neurology 1996; 47: 148–54

    Article  PubMed  CAS  Google Scholar 

  10. Vanacore N, Bonifati V, Fabrini G, et al. Smoking habits in multiple system atrophy and progressive supranuclear palsy. Neurology 2000; 54: 114–9

    Article  PubMed  CAS  Google Scholar 

  11. Brown J, Lantos P, Stratton M, et al. Familial progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1993; 56:473–6

    Article  PubMed  CAS  Google Scholar 

  12. Tetrud JW, Golbe LI, Forno LS, et al. Autopsy-proven progressive supranuclear palsy in two siblings. Neurology 1996; 46: 931–4

    Article  PubMed  CAS  Google Scholar 

  13. de Yebenes JG, Sarasa JL, Daniel SE, et al. Familial progressive supranuclear palsy: description of a pedigree and review of the literature. Brain 1995; 118: 1095–103

    Article  PubMed  Google Scholar 

  14. Mirra SS, Schneider JA, Gearing M. Neuropathology of movement disorders: an overview. In: Watts RL, Koller WC, editors. Movement disorders: neurologic principles and practice. New York: McGraw-Hill, 1997: 125–34

    Google Scholar 

  15. Golbe LI. Progressive supranuclear palsy. In: Watts RL, Koller WC, editors. Movement disorders: neurologic principles and practice. New York: McGraw-Hill, 1997: 279–95

    Google Scholar 

  16. Drubin DG, Kirscher MW. Tau protein in living cells. J Cell Biol 1986; 103: 2739–46

    Article  PubMed  CAS  Google Scholar 

  17. Golbe LI. Progressive supranuclear palsy in the molecular age. Lancet 2000; 356: 870–1

    Article  PubMed  CAS  Google Scholar 

  18. Gearing M, Olson DA, Watts RL, et al. Progressive supranuclear palsy: neuropathologic and clinical heterogeneity. Neurology 1994; 44: 1015–24

    Article  PubMed  CAS  Google Scholar 

  19. Litvan I, Hauw JJ, Bartko JJ, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 1996; 55:97–105

    Article  PubMed  CAS  Google Scholar 

  20. Daniel SE, de Bruin VMS, Lees AJ. The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal. Brain 1995; 118: 759–70

    Article  PubMed  Google Scholar 

  21. Kish SJ, Chang LJ, Mirchandani L, et al. Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. Ann Neurol 1985; 18:530–6

    Article  PubMed  CAS  Google Scholar 

  22. Pascual J, Berciano J, Grijalba B, et al. Dopamine Dl and D2 receptors in progressive supranuclear palsy: an autoradiographic study. Ann Neurol 1992; 32: 703–7

    Article  PubMed  CAS  Google Scholar 

  23. Ruberg M, Javoy-Agid F, Hirsch E, et al. Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol 1985; 18:523–9

    Article  PubMed  CAS  Google Scholar 

  24. Malessa S, Hirsch EC, Cervera P, et al. Progressive supranuclear palsy: loss of choline-acetyltransferase-like immuno-reactive neurons in the pontine reticular formation. Neurology 1991; 41: 1593–7

    Article  PubMed  CAS  Google Scholar 

  25. Swerdlow RH, Golbe LI, Parks JK, et al. Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy. J Neurochem 2000; 75(4): 1681–94

    Article  PubMed  CAS  Google Scholar 

  26. Odetti P, Garibaldi S, Norese R, et al. Lipoperoxidation is selectively involved in progressive supranuclear palsy. J Neuropathol Exp Neurol 2000; 59(5): 393–7

    PubMed  CAS  Google Scholar 

  27. Dickson DW. Neurodegenerative diseases with cytoskeletal pathology: a biochemical classification. Ann Neurol 1997; 42: 541–4

    Article  PubMed  CAS  Google Scholar 

  28. Baker M, Litvan I, Houlden H, et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 1999; 8(4): 711–5

    Article  PubMed  CAS  Google Scholar 

  29. Flament S, Delacourte A, Verny M, et al. Abnormal tau proteins in progressive supranuclear palsy —similarities and differences with the neurofibrillary degeneration of the Alzheimer type. Acta Neuropathol (Berl) 1991; 81: 591–6

    Article  CAS  Google Scholar 

  30. Higgins JJ, Golbe LI, De Biase A, et al. An extended 5-tau susceptibility haplotype in progressive supranuclear palsy. Neurology 2000; 55: 1364–7

    Article  PubMed  CAS  Google Scholar 

  31. Conrad C, Andreadis A, Trojanowski JQ, et al. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol 1997; 41: 277–81

    Article  PubMed  CAS  Google Scholar 

  32. Oliva E, Tolosa E, Ezquerra M, et al. Significant changes in the tau AO and A3 alleles in progressive supranuclear palsy and improved genotyping by silver detection. Arch Neurol 1998; 55: 1122–4

    Article  PubMed  CAS  Google Scholar 

  33. Morris HR, Janssen JC, Bandmann O, et al. The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases. J Neurol Neurosurg Psychiatry 1999; 66(5): 665–7

    Article  PubMed  CAS  Google Scholar 

  34. Hoenicka J, Perez M, Perez-Tur J, et al. The tau gene A0 allele and progressive supranuclear palsy. Neurology 1999; 53(6): 1219–25

    Article  PubMed  CAS  Google Scholar 

  35. Molinuevo JL, Valldeoriola F, Alegret M, et al. Progressive supranuclear palsy: earlier age of onset in patients with the % protein A0/A0 genotype. J Neurol 2000; 247: 206–8

    Article  PubMed  CAS  Google Scholar 

  36. Higgins JJ, Adler RL, Loveless JM. Mutational analysis of the tau gene in progressive supranuclear palsy. Neurology 1999; 53: 1421–4

    Article  PubMed  CAS  Google Scholar 

  37. Hutton M. Missense and splice site mutations in tau associated with FTDP-17: multiple pathogenic mechanisms. Neurology 2001; 56(4) Suppl.: S21–5

    Article  PubMed  CAS  Google Scholar 

  38. Bonifati V, Joosse M, Nicholl DJ, et al. The tau gene in progressive supranuclear palsy: exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the disease-associated H1 haplotype in Italian cases. Neurosci Lett 1999; 274(1): 61–5

    Article  PubMed  CAS  Google Scholar 

  39. Tabaton M, Rolled M, Masturzo P, et al. Apolipoprotein E ε 4 allele is not increased in progressive supranuclear palsy. Neurology 1995; 45: 1764–5

    Article  PubMed  CAS  Google Scholar 

  40. Litvan I, Saunders AM. Apolipoprotein E4 (Epsilon) allele does not affect the onset or symptom severity in progressive supranuclear palsy. Arch Neurol 1998; 55: 752–4

    Article  PubMed  CAS  Google Scholar 

  41. Morris HR, Vaughan JR, Datta SR, et al. Multiple system atrophy/progressive supranuclear palsy: alpha-synuclein, synphilin, tau, and APOE. Neurology 2000; 55(12): 1918–20

    Article  PubMed  CAS  Google Scholar 

  42. Caparros-Lefebvre D, Elbaz A, Caribbean Parkinsonism Study Group. Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Lancet 1999; 354: 281–6

    Article  PubMed  CAS  Google Scholar 

  43. McGeer PL, Schwab C, McGeer EG, et al. Familial nature and continuing morbidity of the amyotrophic lateral sclerosis-parkinsonism dementia complex of Guam. Neurology 1997; 49: 400–9

    Article  PubMed  CAS  Google Scholar 

  44. Birdi S, Rajput A, Fenton M, et al. Progressive supranuclear palsy diagnosis and confounding features: report of 16 autop-sied cases. Movement Disorders. In press

  45. Robbins TW, James M, Owen AM, et al. Cognitive deficits in progressive supranuclear palsy, Parkinson’s disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. J Neurol Neurosurg Psychiatry 1994; 57: 79–88

    Article  PubMed  CAS  Google Scholar 

  46. Bergeron C, Pollanen MS, Weyer L, et al. Cortical degeneration in progressive supranuclear palsy. A comparison with cortical-basal ganglionic degeneration. J Neuropathol Exp Neurol 1997; 56(6): 726–34

    PubMed  CAS  Google Scholar 

  47. Leigh RJ, Newman SA, King WM. Vertical gaze disorders. In: Lennerstrand G, Zee DS, Keller EL, editors. Functional basis of ocular motility disorders. Oxford: Pergamon, 1982: 257–66

    Google Scholar 

  48. Pierrot-Deseilligny C, Rivaud S, Pillon B, et al. Lateral visually-guided saccades in progressive supranuclear palsy. Brain 1989; 112: 471–87

    Article  PubMed  Google Scholar 

  49. Vidailhet M, Rivaud S, Gouider-Khouja N, et al. Eye movements in Parkinsonian syndromes. Ann Neurol 1994; 35: 420–6

    Article  PubMed  CAS  Google Scholar 

  50. Perkin GD, Lees AJ, Stern GM, et al. Problems in the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Can J Neurol Sci 1978; 5(2): 167–73

    Google Scholar 

  51. Collins S, Ahlskog JE, Parisi JE, et al. Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. J Neurol Neurosurg Psychiatry 1995; 58: 167–73

    Article  PubMed  CAS  Google Scholar 

  52. Malessa S, Gaymard B, Rivaud S, et al. Role of pontine nuclei damage in smooth pursuit impairment of progressive supranuclear palsy: a clinical-pathologic study. Neurology 1994; 44: 716–21

    Article  PubMed  CAS  Google Scholar 

  53. Halliday GM, Hardman CD, Cordato NJ, et al. A role for the substantia nigra pars reticulata in the gaze palsy of progressive supranuclear palsy. Brain 2000; 123 (Pt 4): 724–32

    Article  PubMed  Google Scholar 

  54. Leygonie F, Thomas J, Degos JD, et al. Troubles du sommeil dans la maladie de Steele-Richardson. Etude polygraphique de 3 case. Rev Neurol (Paris) 1976; 2: 125–36

    Google Scholar 

  55. Gross RA, Spehlman R, Daniels JC. Sleep disturbances in progressive supranuclear palsy. Electroenceph Clin Neuro-physiol 1978; 45: 16–25

    Article  CAS  Google Scholar 

  56. Perret JL, Jouvet M. Etude du sommeil dans la paralysie supra-nucleaire progressive. Electroenceph Clin Neurophysiol 1980; 49:323–9

    Article  PubMed  CAS  Google Scholar 

  57. Aldrich MS, Foster NL, White RF, et al. Sleep abnormalities in progressive supranuclear palsy. Ann Neurol 1989; 25: 577–81

    Article  PubMed  CAS  Google Scholar 

  58. Zweig RM, Whitehouse PJ, Casanova MF, et al. Loss of pedunculopontine neurons in progressive supranuclear palsy. Ann Neurol 1987; 22: 18–25

    Article  PubMed  CAS  Google Scholar 

  59. Shiromani PJ, Armstrong DM, Berkowitz A, et al. Distribution of choline ace tyltransferase immunoreactive somata in the feline brainstem: implications for REM sleep generation. Sleep 1988; 1: 1–16

    Google Scholar 

  60. Imai H, Nakamura T, Kondo T, et al. Dopa-unresponsive pure akinesia or freezing — a condition within a wide spectrum of PSP? Adv Neurol 1993; 60: 622–5

    PubMed  CAS  Google Scholar 

  61. Riley DE, Fogt N, Leigh RJ. The syndrome of ‘pure akinesia’ and its relationship to progressive supranuclear palsy. Neurology 1994; 44: 1025–9

    Article  PubMed  CAS  Google Scholar 

  62. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richard-son-Olszewski syndrome): report of the NINDS-SPSP International Workshop. Neurology 1996; 47: 1–9

    Article  PubMed  CAS  Google Scholar 

  63. Litvan I, Agid Y, Jankovic J, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 1996; 46: 922–30

    Article  PubMed  CAS  Google Scholar 

  64. Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996; 61: 615–20

    Article  Google Scholar 

  65. Duvoisin R, Yahr MD. Encephalitis and parkinsonism. Arch Neurol 1965; 12: 227–39

    Article  PubMed  CAS  Google Scholar 

  66. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism: a prospective study. Can J Neurol Sci 1991; 18: 275–8

    PubMed  CAS  Google Scholar 

  67. Lang AE, Riley DE, Bergeron C. Cortical-basal ganglionic degeneration. In: Calne DB, editor. Neurodegenerative diseases. Philadelphia: W. B. Saunders Co., 1994: 877–94

    Google Scholar 

  68. Foster NL, Wilhelmsen K, Sima AAF, et al. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Ann Neurol 1997; 41: 706–15

    Article  PubMed  CAS  Google Scholar 

  69. McKeth IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB international workshop. Neurology 1996; 47: 1113–24

    Article  Google Scholar 

  70. Ambrosetto P, Kim M, et al. Progressive supranuclear palsy [letter]. Arch Neurol 1981; 38(10): 672

    Article  PubMed  CAS  Google Scholar 

  71. Savoiardo M, Girotti F, Strada L, et al. Magnetic resonance imaging in progressive supranuclear palsy and other parkinsonian disorders. J Neural Transm 1994; 98 Suppl. 42: 93–110

    Article  Google Scholar 

  72. Haldeman S, Goldman JW, Hyde J, et al. Progressive supranuclear palsy, computed tomography, and response to antiparkinsonian drugs. Neurology 1981; 31: 442–5

    PubMed  CAS  Google Scholar 

  73. Yagishita A, Oda M. Progressive supranuclear palsy: MRI and pathological findings. Neuroradiology 1996; 38 (1 Suppl.): S60–6

    Article  PubMed  Google Scholar 

  74. Schonfeld SM, Golbe LE, Sage JI, et al. Computed tomographic findings in progressive supranuclear palsy: correlation with clinical grade. Mov Disord 1987; 2: 263–78

    Article  PubMed  CAS  Google Scholar 

  75. Schrag A, Good CD, Miszkiel K, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000; 54: 697–702

    Article  PubMed  CAS  Google Scholar 

  76. Schwarz J, Tatsch K, Arnold G, et al. 1231-Iodobenzamide-SPECT in 83 patients with de novo parkinsonism. Neurology 1993; 43 (6 Suppl.): S17–20

    PubMed  CAS  Google Scholar 

  77. Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology 2000; 55: 1540–7

    Article  Google Scholar 

  78. Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28: 547–55

    Article  PubMed  CAS  Google Scholar 

  79. Sawle GV, Playford ED, Burn DJ, et al. Separating Parkinson’s disease from normality: discriminant function analysis of fluorodopa F 18 positron emission tomography data. Arch Neurol 1994; 51: 237–43

    Article  PubMed  CAS  Google Scholar 

  80. Brooks DJ, Ibanez V, Sawle GV, et al. Striatal D2 receptor status in patients with Parkinson’s disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11 C-raclopride and positron emission tomography. Ann Neurol 1992; 31: 184–92

    Article  PubMed  CAS  Google Scholar 

  81. Blin J, Baron J-C, Dubois B, et al. Positron emission tomography study in progressive supranuclear palsy: brain hypo-metabolic pattern and clinicometabolic correlations. Arch Neurol 1990; 47:747–52

    Article  PubMed  CAS  Google Scholar 

  82. Burn DJ, Rinne JO, Quinn NP, et al. Striatal opioid receptor binding in Parkinson’s disease, striatonigral degeneration and Stelle-Richardson-Olszewski syndrome. A[llC]diprenorphine PET study. Brain 1995; 118: 951–8

    Article  PubMed  Google Scholar 

  83. Davie CA, Barker GJ, Machado C, et al. Proton magnetic resonance spectroscopy in Steele-Richardson-Olszewski syndrome. Mov Disord 1997; 12(5): 767–71

    Article  PubMed  CAS  Google Scholar 

  84. Jankovic J, Friedman DI, Pirozzolo FJ, et al. Progressive supranuclear palsy: motor, neurobehavioral, and neuro-ophthalmic findings. In: Streifler MB, Korczyn AD, Melamed E, et al., editors. Parkinson’s disease: anatomy, pathology, and therapy. Advances in Neurology. Vol. 53. New York: Raven Press, 1990: 293–304

    Google Scholar 

  85. Su PC, Goldensohn ES. Progressive supranuclear palsy: electrographic studies. Arch Neurol 1973; 29: 183–6

    Article  Google Scholar 

  86. Kofier M, Muller J, Reggiani L, et al. Somatosensory evoked potentials in progressive supranuclear palsy. J Neurol Sci 2000; 179 Suppl. 1–2: 85–91

    Google Scholar 

  87. Tolosa ES, Zeese JA. Brainstem auditory evoked responses in progressive supranuclear palsy [letter]. Ann Neurol 1979; 6(4): 369

    Article  PubMed  CAS  Google Scholar 

  88. Ondo W, Warrior D, Overby A, et al. Computerized posturogra-phy analysis of progressive supranuclear palsy: a case control comparison with Parkinson’s disease and healthy controls. Arch Neurol 2000; 57(10): 1464–9

    Article  PubMed  CAS  Google Scholar 

  89. Gross M. L-dopa for progressive supranuclear palsy. Lancet 1969; II: 1359–60

    Google Scholar 

  90. Klawans HL. L-dopa for progressive supranuclear palsy [letter]. Lancet 1969; II: 1359

    Article  Google Scholar 

  91. Jenkins R. L-dopa for progressive supranuclear palsy [letter]. Lancet 1969; II: 742

    Article  Google Scholar 

  92. Rajput AH, Rozdilsky B, Rajput A, et al. Levodopa efficacy and pathological basis of parkinson syndrome. Clin Neuro-pharmacol 1990; 13(6): 553–8

    CAS  Google Scholar 

  93. De Renzi E, Vignolo LA. L-dopa for progressive supranuclear palsy [letter]. Lancet 1969; II: 1360

    Google Scholar 

  94. Klawans HL, Ringel SP. Observations on the efficacy of L-dopa in progressive supranuclear palsy. Eur Neurol 1971; 5: 115–29

    Article  PubMed  Google Scholar 

  95. Wagshul A, Daroff RB. L-dopa for progressive supranuclear palsy. Lancet 1969; II: 105–6

    Article  Google Scholar 

  96. Dehaene I, Bogaerts M. L-dopa in progressive supranuclear palsy [letter]. Lancet 1970; II: 470

    Article  Google Scholar 

  97. Jackson JA, Jankovic J, Ford J. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol 1983; 13:273–8

    Article  PubMed  CAS  Google Scholar 

  98. Jankovic J. Controlled trial of pergolide mesylate in Parkinson’s disease and progressive supranuclear palsy. Neurology 1983; 33: 505–7

    Article  PubMed  CAS  Google Scholar 

  99. Weiner WJ, Minagar A, Shulman LM. Pramipexole in progressive supranuclear palsy. Neurology 1999; 52: 873–4

    Article  PubMed  CAS  Google Scholar 

  100. Kertzman C, Robinson DL, Litvan I. Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy. Arch Neurol 1990; 47: 1346–50

    Article  PubMed  CAS  Google Scholar 

  101. Litvan I, Gomez C, Atack JR, et al. Physostigmine treatment of progressive supranuclear palsy. Ann Neurol 1989; 26: 404–7

    Article  PubMed  CAS  Google Scholar 

  102. Frattali CM, Sonies BC, Chi-Fishman G, et al. Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: a pilot study. Dysphagia 1999; 14(3): 165–8

    Article  PubMed  CAS  Google Scholar 

  103. Neophytides A, Lieberman AN, Goldstein M, et al. The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1982; 45: 261–3

    Article  PubMed  CAS  Google Scholar 

  104. Rafal RD, Grimm RJ. Progressive supranuclear palsy: functional analysis of the response to methysergide and antiparkinsonian agents. Neurology 1981; 31: 1507–18

    Article  PubMed  CAS  Google Scholar 

  105. Paulson GW, Lowery HW, Taylor GC. Progressive supranuclear palsy: pneumoencephalography, electronystagmography and treatment with methysergide. Eur Neurol 1981; 20: 13–6

    Article  PubMed  CAS  Google Scholar 

  106. Duncombe AS, Lees AJ. Methysergide in progressive supranuclear palsy [letter]. Neurology 1985; 35: 936–7

    Article  PubMed  CAS  Google Scholar 

  107. Kvale JN. Amitriptyline in the management of progressive supranuclear palsy. Arch Neurol 1982; 38: 387–8

    Article  Google Scholar 

  108. Newman GC. Treatment of progressive supranuclear palsy with tricyclic antidepressants. Neurology 1985; 35: 1189–93

    Article  PubMed  CAS  Google Scholar 

  109. Ghika J, Tennis M, Hoffman E, et al. Idazoxan treatment in progressive supranuclear palsy. Neurology 1991; 41: 986–91

    Article  PubMed  CAS  Google Scholar 

  110. Daniele A, Albanese A, Gainotti G, et al. Zolpidem in Parkinson’s disease. Lancet 1997; 349: 1222–3

    Article  PubMed  CAS  Google Scholar 

  111. Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy. N Engl J Med 1999; 341(7): 543–4

    Article  PubMed  CAS  Google Scholar 

  112. Rajput AH, Uitti RJ, Fenton ME, et al. Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Related Disord 1998; 3(4): 211–4

    Google Scholar 

  113. Barclay CL, Duff J, Sandor P, et al. Limited usefulness of electroconvulsive therapy in progressive supranuclear palsy. Neurology 1996; 46: 1284–6

    Article  PubMed  CAS  Google Scholar 

  114. Polo KB, Jabbari B. Botulinum toxin-A improves the rigidity of progressive supranuclear palsy. Ann Neurol 1994; 35: 237–9

    Article  PubMed  CAS  Google Scholar 

  115. Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 1993; 16: 338–46

    Article  PubMed  CAS  Google Scholar 

  116. Kompoliti K, Goetz CG, Litvan I, et al. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 1998; 55: 1099–102

    Article  PubMed  CAS  Google Scholar 

  117. Fabbrini G, Barbanti P, Bonifati V, et al. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand 2001; 103: 123–5

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Supported by a grant from Saskatchewan Parkinson’s Disease Foundation.

Author information

Authors and Affiliations

  1. Division of Neurology, Royal University Hospital, University of Saskatchewan, 103 Hospital Drive, Saskatchewan, Saskatoon, S7N 0W8, Canada

    Alex Rajput & Ali H. Rajput

Authors
  1. Alex Rajput
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ali H. Rajput
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alex Rajput.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rajput, A., Rajput, A.H. Progressive Supranuclear Palsy. Drugs Aging 18, 913–925 (2001). https://doi.org/10.2165/00002512-200118120-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200118120-00003

Keywords

Search

Navigation